A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants

NCT04543383 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Milvexian
BIOLOGICAL: 4-Factor Prothrombin Complex Concentrate (4F-PCC)
BIOLOGICAL: Recombinant Human Factor VIIa (rFVIIa)
BIOLOGICAL: Placebo matching to 4F-PCC
BIOLOGICAL: Placebo matching to rFVIIa

Sponsor

Janssen Research & Development, LLC